drugset / Trial / NCT02763007

An Extension Study of PEAK Trial

NCT02763007

Phase 4 Terminated 41 enrolled Kun-Ho Yoon Takeda · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Double blind, three arm, comparative intervention trial for 24 weeks(PEAK study) with open label extension trial for 28 weeks followed by 2 year observational study.

Timeline

Start
2016-05-18
Primary completion
2018-12-19
Completion
2019-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg
Subject Pioglitazone Small molecule 30 mg